Is the Lord Jones Acquisition the Right Move for Cronos Group (TSX:CRON)?

Canadian cannabis producers have been looking for ways to penetrate the U.S. market in whatever way that they can. Last week, Cronos Group (TSX:CRON)(NASDAQ:CRON) announced that it was going to be acquiring Redwood Holding Group for approximately US$300 million in a cash-and-stock deal. It’s a big move for Cronos, as it will get access to Lord Jones, a brand owned by…

Read More

The Best Stocks to Get Exposure to the Defensive Healthcare Sector

The health care sector in Canada does not get much attention. Understandably so, as it makes up a very small percent of the TSX, and there are not many large companies to choose from. So as Canadian investors, we have to get a little creative to meet our goal of exposure to the defensive healthcare sector. First, we can look…

Read More

Over 2,000 Atlantans flock to Central Park for second annual Sharecare Heartbeat Festival

Sharecare

Fulton County Board of Commissioners declares “Sharecare Day” at family-friendly festival aimed at helping people live happier, healthier lives ATLANTA, April 17, 2019 (GLOBE NEWSWIRE) — On Saturday, April 13, 2019, more than 2,000 people gathered in Central Park in Atlanta’s Old Fourth Ward neighborhood for the second annual Sharecare Heartbeat Festival, a free, family-friendly event that provides a range…

Read More

Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy

Scholar Rock Holding Corporation

Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to checkpoint blockade therapy (CBT) TGFβ1-specific inhibition by SRK-181-mIgG1 was sufficient to render both TGFβ1-expressing and TGFβ1/TGFβ3 co-expressing mouse tumor models sensitive to anti-PD1 immunotherapy, suggesting TGFβ1 is the key isoform contributing to CBT resistance Combination…

Read More